About Selventa
Selventa is a company based in Cambridge (United States) founded in 2001. It operates as a B2B. Selventa has raised $11.96 million across 3 funding rounds from investors including Flagship Pioneering and Pappas Capital. Selventa operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Selventa Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$11.96 M (USD)
in 3 rounds
-
Latest Funding Round
$4.96 M (USD), Series A
Nov 28, 2011
-
Investors
Flagship Pioneering
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Selventa
Selventa has successfully raised a total of $11.96M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $4.96 million completed in November 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Selventa
Selventa has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Flagship Pioneering and Pappas Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC firm focusing on life science sector
|
Locked | Locked | Locked | |
|
Life sciences-focused venture capital firm
|
Locked | Locked | Locked |
Investor details for Selventa
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Selventa
Investment portfolio details for Selventa
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Selventa
Detailed financials for Selventa
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Selventa Comparisons
Peer comparison for Selventa
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Selventa
Selventa operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| Locked | Locked | Locked |
Diagnostic services are provided through laboratories and radiology units.
|
Detailed competitors of Selventa
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Selventa
Complete news archive for Selventa
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Selventa
Selventa was founded in 2001 and raised its 1st funding round 2 years after it was founded.
Selventa is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Selventa is a funded company, having raised a total of $11.96M across 3 funding rounds to date.
Selventa, based in Cambridge, focuses on providing healthcare solutions, advancing biotech innovations, offering diagnostic solutions, and personalized medicine. Selventa specializes in diagnostics for personalized medicine, advancing tailored healthcare solutions. The company prioritizes operational excellence, innovation, and customer-centric approaches for success.
Selventa's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
Selventa has 2 investors. Key investors include Flagship Pioneering, and Pappas Capital.